Canis ISSN: 2398-2942


Synonym(s): Suprelorin®

Contributor(s): Monica Ptaszynska, Angelika von Heimendahl



  • Deslorelin.

Class of drug

  • Gonadotrophin-releasing hormone (GnRH) agonist.


Chemical name

  • Available veterinary formulation contains deslorelin as deslorelin acetate.

Physical properties

  • White to pale yellow cylindrical implant (size of a microchip).
  • Implant is supplied in a pre-loaded implanter.

Storage requirements

  • Store in refrigerator (2-8°C).
  • Do not freeze.
  • Shelf-life of product packaged for sale: 2 years.


This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login


  • For the induction of temporary infertility in healthy, entire, sexually mature male dog. An alternative to surgical castration Castration.

Reported indications in dogs outside of the licensed use

Male dogs

  • Undesired/overexpressed sexual behavior: as the treatment lowers libido and male sexual behavior, it can be used to determine whether high testosterone production is the underlying cause and whether castration would be the right solution.
  • Treatment with slow release formulations of deslorelin was reported in the management of hormone-dependent benign prostate gland hyperplasia Prostate: benign hyperplasia and hypertrophy.

Female dogs

  • Treatment with slow release formulations of deslorelin was reported as temporary inhibition of estrous cycle and ovulation.
  • Due to the initial stimulation of FSH and LH release, deslorelin in slow release formulation was used for induction of estrus and ovulation in female dogs.


This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login


This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login


with other drugs

  • None known.

Warnings for personnel handling the product

  • Women in childbearing age should avoid contact with the product or wear disposable plastic gloves when handling the product.
  • Pregnant women should handle the product with extreme care.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading


Refereed papers

  • Recent references from PubMed and VetMed Resource.
  • Fontaine E, Fontbonne A (2011) Clinical use of GnRH agonists in canine and feline species. Reprod Domest Anim 46, 344-353 PubMed.
  • Goericke-Pesch S, Spang A, Schulz M, Ozalp G, Bergmann M, Ludwig C, Hoffmann B (2009) Recrudescence of spermatogenesis in the dog following downregulation using a slow release GnRH agonist implant. Reprod Dom Anim 44, 302-308 PubMed.
  • Romagnoli S, Stelletta C, Milani C, Gelli D, Falomo M E, Mollo A (2009) Clinical use of deslorelin for the control of reproduction in the bitch. Reprod Dom Anim 44(Suppl. 2), 36-39 PubMed.
  • Junaidi A et al (2007) Pituitary and testicular endocrine responses to exogenous gonadotrophin-releasing hormone (GNRH) and luteinising hormone in male dogs treated with GNRH agonist implants. Reprod Fertil Dev 19(8), 891-898 PubMed.
  • Trigg T, Doyle A, Walsh J, Swangchan-uthai T (2006) A review of advances in the use of the GnRH agonist deslorelin in control of reproduction. Theriogenology 66,1507-1512 PubMed.
  • Volkmann D, Kutzler M, Wheeler R, Krekeler N (2006) The use of deslorelin implants for the synchronization of estrous bitches. Theriogenology 66, 1497-1501 PubMed.
  • Ponglowhapan S, Lohachit C, Swangchan-uthai T, Trigg T E (2002) Influences of subcutaneous deslorelin implantation on fertility in male dogs. Reprod Dom Anim 37, 246.
  • Trigg T E, Wright P J, Armour A F, Williamson P E, Junaidi A, Martin G B et al(2001) Use of a GnRH analogue implant to produce reversible, long term suppression of reproductive function ofmale and female domestic dogs. J Reprod Fertil 57, 255-261 PubMed.
  • Wright P J, Verstegen J P, Onclin K, Jochle W, Armour A F, Martin G B, Trigg T E (2001) Suppression of the oestrous response of bitches to the GnRH analogue deslorelin by progestin. J Repro Fertil Suppl 57, 263-268 PubMed.

Other sources of information

  • Fontaine E, Fontbonne A (2010) Use of deslorelin to control fertility in the bitch. Symposium deslorelin: deslorelin in practice,7th EVSSAR Congress. Louvain la Neuve, Belgium, pp. 1517.
  • de Gier J, Winke (2010) Use of deslorelin to control hypersexuality in male dogs. Symposium deslorelin: deslorelin in practice, 7th EVSSAR Congress. Louvain la Neuve, Belgium; pp 9-10.
  • Palm J, Reichler I (2010) Effectiveness of deslorelin acetate for the suppression of heat in the bitch. 7th EVSSAR Congress Louvain La Neuve, Belgium.p 87.
  • Jurczak A, Domoslawska A, Janowski T, Zdunczyk S (2010) Treatment of benign prostatic hyperplasia (BPH) in dogs using GnRH agonist implant Suprelorin®- preliminary results. Proceedings 7th EVSSAR congress. Louvain la Neuve, Belgium; p 118.
  • Ponglowhapan S, Lohachit C (2010) Clinical use of GnRH agonist Deslorelin in benign prostatic hyperplasia in dogs. Proceedings 7th EVSSAR Congress. Louvain la Neuve, Belgium. p 140.
  • Corrada Y, Hermo G, De la Sota PE, Garcia P, Trigg T, Gobello C (2006) A short term progestin treatment prevents estrus induction by a GnRH agonist implant in anestrous bitches. Proceedings of 5th Biannual EVSSAR Congress, Budapest, p 278.
  • Ponglowhapan S, Lohachit C, Swangchanuthai T, Trigg T E (2002) The effect the GnRH agonist deslorelin on prostatic volume in dogs. Proceedings of the 3rd EVSSAR Meeting. p 150.
  • Kutzler M A, Wheeler R, Lamb S V, Volkmann D H (2002) Deslorelin implant administration beneath the vulvar mucosa for the induction of synchronous estrus in bitchesProceedings of the 3rd EVSSAR Meeting. p 96.
  • Kutzler M A, Wheeler R, Volkmann D H (2001) Deslorelin implants for induction of estrus in bitches. Proceedings of the 2nd EVSSAR Meeting; 2001. pp 160-161.


  • Peptech Animal Health, Australia;
  • Virbac Ltd, Woolpit Business Park, Bury St Edmonds, Suffolk IP30 9UP, UK.